259 related articles for article (PubMed ID: 19138952)
1. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
Lucia MS; Darke AK; Goodman PJ; La Rosa FG; Parnes HL; Ford LG; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):167-73. PubMed ID: 19138952
[TBL] [Abstract][Full Text] [Related]
2. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
Lucia MS; Epstein JI; Goodman PJ; Darke AK; Reuter VE; Civantos F; Tangen CM; Parnes HL; Lippman SM; La Rosa FG; Kattan MW; Crawford ED; Ford LG; Coltman CA; Thompson IM
J Natl Cancer Inst; 2007 Sep; 99(18):1375-83. PubMed ID: 17848673
[TBL] [Abstract][Full Text] [Related]
3. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
[TBL] [Abstract][Full Text] [Related]
4. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
[TBL] [Abstract][Full Text] [Related]
5. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
Villers A
Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice.
Sarvis JA; Thompson IM
Curr Oncol Rep; 2008 Nov; 10(6):529-32. PubMed ID: 18928669
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification.
Ankerst DP; Thompson IM
Arch Ital Urol Androl; 2006 Dec; 78(4):125-9. PubMed ID: 17269614
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
[TBL] [Abstract][Full Text] [Related]
9. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
Epstein JI; Walsh PC; Carmichael M; Brendler CB
JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
[TBL] [Abstract][Full Text] [Related]
10. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
11. Does the level of prostate cancer risk affect cancer prevention with finasteride?
Thompson IM; Tangen CM; Parnes HL; Lippman SM; Coltman CA
Urology; 2008 May; 71(5):854-7. PubMed ID: 18455628
[TBL] [Abstract][Full Text] [Related]
12. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
Redman MW; Tangen CM; Goodman PJ; Lucia MS; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):174-81. PubMed ID: 19138953
[TBL] [Abstract][Full Text] [Related]
13. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
14. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
16. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
17. [The pathologist's perspective on the PCPT trial].
Molinié V; Allory Y
Prog Urol; 2008 Apr; 18 Suppl 3():S47-52. PubMed ID: 18455084
[TBL] [Abstract][Full Text] [Related]
18. The influence of finasteride on the development of prostate cancer.
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
[TBL] [Abstract][Full Text] [Related]
19. Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score.
Ankerst DP; Till C; Boeck A; Goodman PJ; Tangen CM; Thompson IM
Urology; 2013 Nov; 82(5):1076-81. PubMed ID: 24055241
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]